RarePipelinepeopleInnovationCollaborationCareersFinance Advance treatment Skip to main contentSkip to navigationSkip to search
Hansa Biopharma
HNSA (, %) SEK
Hansa Biopharma
Coffee and notepad

Press releases


30 May 2022, 15:55
The Nomination Committee in Hansa Biopharma has completed its nomination work for the Annual General Meeting 2022. It proposes to the Annual General Meeting 2022 for Peter Nicklin to be elected new chair of the Board of Directors of Hansa Biopharma. The current chair Ulf Wiinberg has chosen to not stand for re-election.
23 May 2022, 08:00

· 30 patients with active or chronic active antibody mediated rejection (AMR) episodes post kidney transplantation have been enrolled and randomized 2:1 to imlifidase v.s. standard-of-care
· Completion of enrollment marks an important milestone for Hansa, as the company explores the potential of imlifidase in the post transplantation setting. 
· Acute AMR episod…
21 Apr 2022, 08:00 | Regulatory

· Solid sales growth in Q1 2022
· Market access secured in Germany and in France
· Marketing authorization granted in Israel
· Results from Phase 2 program in anti-GBM published in Journal of American Society of Nephrology (JASN)
Load more

Coffee and notepad


Sign up to receive updates on the latest company news and filings

Choose type

Thank you. You will get an e-mail message to activate your subscription.